Dopamine D3 receptor antagonists as therapeutic agents (Q28259541)

Dopamine receptor signaling

Europe PubMed Central

title

Dopamine D3 receptor antagonists as therapeutic agents (English)

0 references

0 references

Jeffrey N Joyce

1

0 references

Mark J Millan

series ordinal

2

0 references

language of work or name

English

0 references

publication date

1 July 2005

0 references

published in

Drug Discovery Today

0 references

volume

10

0 references

issue

13

0 references

page(s)

917-25

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Human dopamine D(3) receptors mediate mitogen-activated protein kinase activation via a phosphatidylinositol 3-kinase and an atypical protein kinase C-dependent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Adenosine A2A receptor and dopamine D3 receptor interactions: evidence of functional A2A/D3 heteromeric complexes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Dopamine D3 receptors expressed by all mesencephalic dopamine neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Rat striatal and mesencephalic neurons contain the long isoform of the D2 dopamine receptor mRNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

D(3) receptor ligands modulate extracellular dopamine clearance in the nucleus accumbens

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Lack of functional D2 receptors prevents the effects of the D3-preferring agonist (+)-PD 128907 on dialysate dopamine levels

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Phenotypic analysis of dopamine receptor knockout mice; recent insights into the functional specificity of dopamine receptor subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Dopamine D3 receptor agonists produce similar decreases in body temperature and locomotor activity in D3 knock-out and wild-type mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Behavioral effects of dopamine agonists and antagonists in MPTP-lesioned D3 receptor knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Recent advances in the development of dopamine D(3) receptor agonists and antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Progress in developing D3 dopamine receptor ligands as potential therapeutic agents for neurological and neuropsychiatric disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Effects of dopamine D3 receptor antagonists on spontaneous and agonist-reduced motor activity in NMRI mice and Wistar rats: comparative study with nafadotride, U 99194A and SB 277011.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Comparative pharmacology of human dopamine D(2)-like receptor stable cell lines coupled to calcium flux through Galpha(qo5).

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Evidence for regulation of body temperature in rats by dopamine D2 receptor and possible influence of D1 but not D3 and D4 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

The dopamine D3 receptor partial agonist, BP 897, is an antagonist at human dopamine D3 receptors and at rat somatodendritic dopamine D3 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Novel benzopyrano[3,4-c]pyrrole derivatives as potent and selective dopamine D3 receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Influence of dopamine on limbic inputs to the nucleus accumbens

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal period

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Half a century of antipsychotics and still a central role for dopamine D2 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Increased rewarding properties of morphine in dopamine-transporter knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Methamphetamine-induced loss of striatal dopamine innervation in BDNF heterozygote mice does not further reduce D3 receptor concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Changes in the pattern of brain-derived neurotrophic factor immunoreactivity in the rat brain after acute and subchronic haloperidol treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Meta-analysis of DRD3 gene and schizophrenia: ethnic heterogeneity and significant association in Caucasians

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Dopamine D3 receptor gene Ser9Gly variant and schizophrenia: association study and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Dopamine D3 receptor gene not associated with symptomatology of major psychoses

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia--an update

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Association between dopamine D3 receptor gene polymorphisms and schizophrenia in an isolate population

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Role of the dopamine D3 receptor in reactivity to cocaine-associated cues in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Double activity imaging reveals distinct cellular targets of haloperidol, clozapine and dopamine D(3) receptor selective RGH-1756.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Clozapine-, but not haloperidol-, induced increases in deltaFosB-like immunoreactivity are completely blocked in the striatum of mice lacking D3 dopamine receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Hypofrontality in schizophrenia: a meta-analysis of functional imaging studies

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Relationship of behavioural and symptomatic syndromes in schizophrenia to spatial working memory and attentional set-shifting ability.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Antipsychotic drugs: evolving mechanisms of action with improved therapeutic benefits

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Selective antagonism at dopamine D3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Mice lacking dopamine D2 and D3 receptors exhibit differential activation of prefrontal cortical neurons during tasks requiring attention

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

D1 agonist dihydrexidine releases acetylcholine and improves cognitive performance in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

On the trail of a cognitive enhancer for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Comparison of dopamine receptor antagonists on hyperlocomotion induced by cocaine, amphetamine, MK-801 and the dopamine D1 agonist C-APB in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

The dopamine D3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Prepulse inhibition of the acoustically evoked startle reflex in patients with an acute schizophrenic psychosis--a longitudinal study.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

The dopamine D2, but not D3 or D4, receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Design and Synthesis of trans-3-(2-(4-((3-(3-(5-Methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro- 1H-3-benzazepine (SB-414796): A Potent and Selective Dopamine D3 Receptor Antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

D3 dopamine receptor, behavioral sensitization, and psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Does dopamine sensitization underlie the association between schizophrenia and drug abuse?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Blockade of mesolimbic dopamine D3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

Acute administration of the selective D3 receptor antagonist SB-277011A blocks the acquisition and expression of the conditioned place preference response to heroin in male rats

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021

The D3R partial agonist, BP 897, attenuates the discriminative stimulus effects of cocaine and D-amphetamine and is not self-administered

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903491-4

7 January 2021